Loading...
 
Mediterr J Rheumatol 2017;28(4):217-20
Rituximab and lenalidomide combination treatment for rheumatoid arthritis complicated with myelodysplastic syndrome: A case report
Authors Information

1: Rheumatology Department, 417 Army Share Fund Hospital (NIMTS), Athens, Greece
2: Department of Pathophysiology, General Hospital of Athens “Laiko”, Athens, Greece

References
  1. Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch M H, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 2014;73:62-8.
  2. Mekinian A, Braun T, Decaux O, Falgarone G, Toussirot E, Raffray L, et al. Inflammatory arthritis in patients with myelodysplastic syndromes: a multicenter retrospective study and literature review of 68 cases. Medicine (Baltimore) 2014;93:1-10.
  3. Komrokji R S, Kulasekararaj A, Al Ali N H, Kordasti S, Bart-Smith E, Craig B M, et al. Autoimmune diseases and myelodysplastic syndromes. Am J Hematol 2016;91:E280-3.
  4. Anderson L A, Pfeiffer R M, Landgren O, Gadalla S, Berndt S I, Engels E A. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer 2009;100(5):822-8.
  5. Wilson A B, Neogi T, Prout M, Jick S. Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the General Practice Research Database. Cancer Epidemiol 2014;38:544-9.
  6. Tsuji T, Yamasaki H, Tsuda H. Successful treatment with cyclosporine for myelodysplastic syndrome with erythroid hypoplasia following rheumatoid arthritis. Rinsho Ketsueki 2010;51:427-32.
  7. Giagounidis A, Haase S, Germing U, Heinsch M, Aul C. Autoimmune disorders in two patients with myelodysplastic syndrome and 5q deletion. Acta Haematol 2005;113:146-9.
  8. Smolen J S, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77.
  9. Hauser S L, Waubant E, Arnold D L, Vollmer T, Antel J, Fox R J, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676–88.
  10. Coleman M, Lammers P E, Ciceri F, Jacobs I A. Role of rituximab and rituximab biosimilars in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk 2016;16:175–81.
  11. Koutsianas C, Thomas K, Vassilopoulos D. Hepatitis B Reactivation in Rheumatic Diseases: Screening and Prevention. Rheum Dis Clin North Am 2017;43:133-49.
  12. Buch M H, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:909–20.
  13. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf
  14. Salmon J H, Cacoub P, Combe B, Sibilia J, Pallot-Prades B, Fain O, et al. Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry. RMD Open 2015;1(1):e000034.
  15. Yu Q H, Shen Y P, Ye B D, Zhou Y H. Successful use of rituximab in platelet transfusion refractoriness in a multi-transfused patient with myelodysplastic syndrome. Platelets 2015;26:195-6.
  16. Liu W, Wu D, Hu T, Ye B. Efficiency of treatment with rituximab in platelet transfusion refractoriness: a study of 7 cases. Int J Clin Exp Med 2015;8:14080-4.
  17. Dierickx D, Kentos A, Delannoy A. The role of rituximab in adults with warm antibody autoimmune hemolytic anemia. Blood 2015;125:3223-9.
  18. Khellaf M, Charles-Nelson A, Fain O, Terriou L, Viallard J F, Cheze S, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood 2014;124:3228-36.
  19. Simonetta F, Posa M, Villard J, Marceau-Renaut A, Preudhomme C, Samii K, et al. Restoration of hematopoiesis in a case of myelodysplastic syndrome associated with systemic lupus erythematosus treated with rituximab. Ann Hematol 2015;94:1247-9.
  20. Duong V H, Komrokji R S, List A F. Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion. Ther Adv Hematol 2012;3:105–16.
  21. Belickova M, Cermak J, Dostalova Merkerova M, Vesela J, Krejcik Z, Cechova E, et al. Changes associated with lenalidomide treatment in the gene expression profiles of patients with del(5q). Clin Lymphoma Myeloma Leuk 2012;12:375-83.
  22. Lopez-Millan B, Diaz de la Guardia R, Roca-Ho H, García-Herrero C M, Lavoie J R, Rosu-Myles M, et al. Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease. Exp Mol Med 2017;49(2):e290.
  23. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, et al. Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells. Clin Cancer Res 2008;14:4650-7.
  24. Thonhofer R, Kriessmayr M, Thonhofer U, Wipfler E, Uitz E, Bahadori B, et al. Rheumatoid arthritis patients with therapy-induced myelodysplastic syndrome present with long-term remission after recovery. Scand J Rheumatol 2007;36:149–60.
  25. Ertz-Archambault N, Kosiorek H, Taylor G E, Kelemen K, Dueck A, Castro J, et al. Association of Therapy for Autoimmune Disease with Myelodysplastic Syndromes and Acute Myeloid Leukemia. JAMA Oncol 2017;3:936-43.